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ABSTRACT 81 
Recent studies suggest that immune-modulating single nucleotide polymorphisms (SNPs) 82 
influence the risk of developing cancer-related infections. Here, we evaluated whether 36 SNPs 83 
within 14 immune-related genes are associated with the risk of Invasive Aspergillosis (IA) and 84 
whether genotyping of these variants might improve disease risk prediction. We conducted a 85 
case-control association study of 781 immunocompromised patients, 149 of whom were 86 
diagnosed with IA. Association analysis showed that the IL4Rrs2107356 and IL8rs2227307 SNPs were 87 
associated with an increased risk of IA (OR=1.92, 95%CI: 1.20-3.09 and OR=1.73, 1.06-2.81) 88 
whereas the IL12Brs3212227 and IFNγrs2069705 variants were significantly associated with a 89 
decreased risk of developing the infection (OR=0.60, 0.38-0.96 and OR=0.63, 0.41-0.97). An 90 
allogeneic hematopoietic stem cell transplantation (allo-HSCT)-stratified analysis revealed that 91 
the effect observed for the IL4Rrs2107356 and IFNγrs2069705 SNPs was stronger in allo-HSCT 92 
(OR=5.63, 1.20-3.09 and OR=0.24, 0.10-0.59) than in non-HSCT patients, suggesting that the 93 
presence of these SNPs may render patients more vulnerable to infection especially under 94 
severe and prolonged immunosuppressive conditions. Importantly, in vitro studies revealed that 95 
carriers of the IFNγrs2069705C allele showed a significantly increased macrophage-mediated 96 
neutralisation of fungal conidia (P=0.0003) and, under stimulation conditions, produced higher 97 
levels of IFNγ mRNA (P=0.049) and IFNγ and TNFα cytokines (PLPS-96h=0.057, PPHA-96h=0.036 98 
and PLPS+PHA-96h=0.030 and PPHA-72h=0.045, PLPS+PHA-72h=0.018, PLPS-96h=0.058 and PLPS+PHA-99 
96h=0.0058, respectively). Finally, we also observed that the addition of SNPs significantly 100 
associated with IA to a model including clinical variables led to a substantial improvement in the 101 
discriminatory ability to predict the disease (AUC=0.659 vs. AUC=0.564, PLR=5.2•10-4 and 102 
P50.000Perm=9.34•10-5). These findings suggest that the IFNγrs2069705 SNP influences the risk of IA 103 
and that predictive models built with IFNγ, IL8, IL12p70 and VEGFα variants might be used to 104 
predict disease risk and to implement risk-adapted prophylaxis or diagnostic strategies.  105 
 106 
 107 
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INTRODUCTION 110 
Invasive Aspergillosis (IA) is a life-threatening infection caused by Aspergillus spp. that affects 111 
acute myelogenous leukemia (AML) and allogeneic hematopoietic stem cell transplantation (allo-112 
HSCT) patients (1-3). Despite recent improvements in the prophylaxis and treatment of IA, its 113 
incidence and attributable mortality rates remain unacceptably high even among those 114 
individuals who lack established risk factors (4, 5). 115 
  116 
The initial immune response against fungal pathogens such as Aspergillus fumigatus the 117 
principal pathogenic species, mainly relies on phagocytes, endothelial and epithelial cells that 118 
recognize this fungal pathogen through pattern recognition receptors (PRRs) thus leading to 119 
phagocytosis, antigen presentation and production of specific cytokines and chemokines (6, 7). 120 
There are different families of PRRs including C-type lectin receptors (CLRs), Toll-like receptors 121 
(TLRs), RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs) that, in response to 122 
Aspergillus pathogen-associated molecular patterns (PAMPs), activate Th1-, Th2- and Th17-123 
related signalling cascades on phagocytes and non-professional immune cells (8-12). These 124 
intracellular molecular pathways culminate in the production of both pro-inflammatory (13-18) 125 
and anti-inflammatory cytokines (19, 20) and certain chemokines and their receptors (21-23) as 126 
well as in the release of certain proangiogenic factors such as VEGFA and bFGF (17, 24), which 127 
are also key determinants in the immune response against Aspergillus spp.  128 
 129 
Although both innate and adaptive immune responses against A. fumigatus have been 130 
extensively characterized (25, 26), it remains unclear why some immunocompromised subjects 131 
develop invasive or disseminated fungal infections while others in similar clinical conditions do 132 
not. The remarkable genetic variation of immune genes suggests that the presence of specific 133 
genetic variants in these genes may influence their biological function and, consequently, impact 134 
on the risk of developing invasive fungal infections, such as IA. In support of this hypothesis, 135 
recent studies on genetic susceptibility have successfully identified several genetic variants on 136 
PRR genes (DC-SIGN, Dectin-1, TLRs, PTX3 and MBL) (27-40), cytokines (IL1 gene cluster, 137 
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IL10, IL12 and IFNγ) (32, 41-44), chemokines (CXCL10) (45) and immune receptors (TNFR1 138 
and TNFR2) (46, 47) as factors influencing the risk of developing IA. With this background, the 139 
purpose of this study was to comprehensively assess whether the presence of single nucleotide 140 
polymorphisms (SNPs) within 14 immune-modulating genes (IL4, IL4R, IL8, IL8RA, IL8RB, IL10, 141 
IL12A, IL12B, IL13, IFNγ, IFNγR2, CCR5, MIF and VEGF) may influence the risk of developing 142 
IA. We also decided to evaluate the functional role of key variants in modulating immune 143 
responses and whether selected polymorphisms could be used to predict the disease risk. 144 
 145 
MATERIAL AND METHODS 146 
Study design and study population 147 
Here, we analysed whether 36 SNPs within 14 immune-modulating genes were associated with 148 
IA. SNPs selection was based on three criteria: (1) SNPs within immunoregulatory genes that 149 
may affect immune responses, (2) SNPs having laboratory evidence of a biological function 150 
and/or (3) SNPs previously reported as associated with infectious diseases (Table 1). SNPs 151 
were genotyped using KASPar® assays (LGC Genomics KBioscience, London, UK) as 152 
previously described in detail (28). Patient inclusion criteria were either undergoing allo-HSCT or 153 
being diagnosed with acute myeloid leukaemia (AML) or acute lymphoid leukaemia (ALL) and 154 
receiving intensive remission-induction chemotherapy. A total of five hundred and ninety-three 155 
patients were recruited between February 2010 and March 2014 through the aspBIOmics 156 
consortium (www.aspbiomics.eu) and through two Spanish medical institutions (University 157 
Hospital of Salamanca and Clinic University Hospital of Valencia) and a Spanish multicentre 158 
clinical trial (PCRAGA, EU clinical trial number: 2010-019406-17) (48). Based on microbiological 159 
and clinical data, one hundred and thirteen patients were diagnosed with proven or probable IA 160 
according to the revised EORTC/MSG criteria (2008) (49). In order to further confirm significant 161 
associations identified in our population, we extended the analysis to a second patient group 162 
consisting of 188 high-risk patients (36 IA patients and 152 without IA; Table 2) recruited from 163 
two Italian medical institutions (Università Cattolica del S. Cuore, Rome; and University of 164 
Modena and Reggio Emilia, AOU Policlinico, Modena) and from the Virgen de las Nieves 165 
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University hospital (Granada, Spain) between January 2013 and January 2015. This ambitious 166 
study design provided a population of 781 high-risk patients, 149 of whom were diagnosed with 167 
proven and probable IA (19 proven and 130 probable IA). To our knowledge, this is one of the 168 
largest population recruited so far exploring genetic susceptibility to IA. The study was approved 169 
by the ethical review boards of each participating institution. 170 
 171 
Statistical analysis 172 
The Hardy-Weinberg Equilibrium (HWE) tests were performed in the uninfected control group by 173 
a standard observed-expected chi-square (χ2) test. Logistic regression analyses adjusted for 174 
age, gender, country of origin, allo-HSCT and receipt or non-receipt of anti-fungal prophylaxis 175 
were performed to determine significant associations with IA risk. SNPtool (50) and Haploview 176 
were used for linkage disequilibrium (LD) blocks reconstruction and haplotype association 177 
statistics. Block structures were determined according to the method of Gabriel et al. (51). In 178 
order to account for multiple testing, we calculated an adjusted significance level using the Meff 179 
method (52), which consider the number of independent marker loci (MeffLi=31), and the number 180 
of models of inheritance tested (co-dominant, dominant, recessive and log-additive). Detailed 181 
information about this method of multiple testing correction is freely available online at 182 
http://neurogenetics.qimrberghofer.edu.au/SNPSpDlite. Thus, the resulting threshold for the 183 
main effect analysis was 0.0004 ([0.05/31]/4).  184 
 185 
Cell isolation and differentiation 186 
Peripheral blood mononuclear cells (PBMCs) and monocytes were isolated from whole blood 187 
collected from healthy donors after obtaining written informed consent (PI12/02688 and SECVS 188 
014/2015 protocols). PBMCs were isolated by gradient centrifugation using Ficoll-Paque PLUS 189 
(GE Healthcare Bio-Sciences) and monocytes were isolated by immunomagnetic selection of 190 
CD14+ cells (Miltenyi Biotec). Purity of the obtained CD14+ population was assessed by 191 
fluorescence-activated cell sorting analysis. Monocytes were then plated at a density of 5×105 192 
cells/mL in 24-well plates, cultivated for 7 days in complete RPMI 1640 medium supplemented 193 
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with human serum and 20 ng/mL of GM-CSF to allow differentiation into macrophages. The 194 
culture medium was replaced every 3 days. Genotyping of significant SNPs was performed and 195 
either PBMCs or monocytes were grouped according to the genotype of interest. 196 
 197 
Assessment of fungicidal activity 198 
Human monocyte-derived macrophages were infected with conidia from Aspergillus fumigatus at 199 
an effector-to-target ratio of 1:10. To measure the fungicidal ability, macrophages were allowed 200 
to kill the ingested conidia for 2 h. Serial dilutions of macrophage lysates were plated on solid 201 
growth media and following a 2-day incubation, the number of colony-forming units (CFU) was 202 
enumerated and the percentage of CFU inhibition was calculated. In order to avoid a bias due to 203 
differences in internalization rates, the supernatants collected after the co-culture were plated 204 
and compared among different donors.   205 
 206 
IL12p70 and IFNγ stimulation assays. 207 
IL12p70 and IFNγ stimulation assays were performed in PBMCs from healthy donors according 208 
to a previously reported protocol (53). PBMCs were selected according to the IL12Brs3212227 and 209 
IFNγrs2069705 genotypes and were cultured in 2 ml of culture medium RPMI-1640 supplemented 210 
with 10% sterile heat-inactivated fetal bovine serum (FBS) and an antibiotic mixture containing 211 
penicillin, streptomycin and neomycin (Gibco®/Life Technologies) at 37ºC in 5% CO2. PBMCs 212 
from healthy subjects harbouring the IFNγrs2069705T/T (n=8), IFNγrs2069705C/T (n=8) and IFNγrs2069705C/C 213 
(n=3) genotypes were incubated for 72h and 96h with phytohaemagglutinin (PHA, 2μg/ml) alone 214 
or in combination with lypopolysaccharide (LPS, 100ng/ml) and IFNγ, IL12p70, TNF and IL8 215 
levels were determined in triplicate using the Procartaplex, Multiplex Immunoassay 216 
(Affymetrix/eBioscience) according to manufacturer’s recommendations. In parallel, PBMCs 217 
bearing the IL12Brs3212227A/A (n=13), IL12Brs3212227A/C (n=3) and IL12Brs3212227C/C (n=1) genotypes 218 
were treated for 24h and 48h with zymosan (5μg/ml) alone or in combination with LPS 219 
(100ng/ml) and correlation of cytokine levels with the IL12Brs3212227 or IL8rs321227 SNPs was also 220 
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analysed. After the incubation period, supernatants were collected and stored at -80ºC until 221 
cytokine measurement.  222 
 223 
Analysis of IL4R and IFNγ mRNA expression 224 
We measured IL4R and IFNγ mRNA gene expression in blood samples collected from healthy 225 
blood donors but also in monocyte-derived macrophages at baseline and after the stimulation 226 
with conidia from A. fumigatus at an effector-to-target ratio of 1:2 for 8 h. Total RNA from blood or 227 
monocyte-derived macrophages was extracted using RNeasy Mini Kit (QIAGEN) and reverse 228 
transcribed with the iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer’s 229 
instructions. Real-time RT-PCR was performed in an Applied Biosystems 7500HT Fast using 230 
Taqman probe-based gene expression technology (Life Technologies) according to the 231 
manufacturer’s instructions. Statistical significance in gene expression changes was determined 232 
by unpaired t test with Whelch’s correction (assuming unequal variance between groups).  233 
 234 
Analysis of IL4R protein expression on T- and B-lymphocytes and monocytes by flow cytometry 235 
IL4R protein levels were determined in PBMCs carrying the wild-type IL4Rrs2107356G/G (n=13), 236 
heterozygote IL4Rrs2107356A/G (n=24) or mutant IL4Rrs2107356A/A genotypes (n=6) by flow cytometry 237 
following a slightly modified version of a previously reported protocol (54). Briefly, PBMCs (1 x 238 
106) were pre-incubated with PBS supplemented with 5% FBS + 2 mM EDTA for 10 minutes to 239 
block Fc receptors. Subsequently, cells were stained for 45 minutes at ambient temperature with 240 
mouse anti-human antibodies to determine the levels of IL4R protein expression on CD3+T-cells, 241 
CD19+B-cells and CD14+ monocytes. The negative control consisted of cells incubated with a 242 
mouse PE-IgG1 Kappa (BD Pharmingen). The analysis was performed according to the flow 243 
cytometric cell surface staining method and the following antibodies were used: phycoerythrin 244 
(PE)-conjugated CD124+, Peridin chlorophyll protein (PerCP)-conjugated CD14+, allophycocyanin 245 
(APC)-eFluor®780-conjugated CD3+ and fluorescein isothiocyanate (FITC)–conjugated CD19+ 246 
antibodies (BD Pharmingen). Cells were acquired on a BD FACSVerse flow cytometer (BD 247 
Biosciences) and the data were analysed using the FlowJo software (TreeStar Inc.). Median 248 
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fluorescence intensity (MFI) of the positive population was recorded for each cell type and 249 
statistical differences were evaluated using an unpaired t-test with Welch’s correction (two-tailed 250 
P value). 251 
 252 
Predictive models and discriminative accuracy 253 
The value of immune-modulating polymorphisms for prediction of IA was examined using 254 
stepwise logistic regression analysis. A prediction model was built that included age, gender, 255 
allo-HSCT and anti-fungal prophylactic status, and those genetic variants that showed significant 256 
associations with IA in the single-SNP analysis (P<0.05; phases 1+2). Then, using p-values as a 257 
selection criterion, variables with the highest p-value were dropped and analyses were finalized 258 
when all variables reached statistical significance (P<0.05). A predictive model with a similar 259 
number of “non-significant SNPs” (P>0.10) was also built. The area under the curve (AUC) of a 260 
receiver operating characteristic (ROC) curve analysis was used to assess the discriminative 261 
accuracy of each particular model compared with a reference model including only demographic 262 
and clinical variables as covariates (age, gender, allo-HSCT and anti-fungal prophylaxis status). 263 
A -2 log likelihood ratio (LR) test was used to determine whether predictive models including 264 
genetic information were statistically different when compared with the reference model. Finally, 265 
we run a randomization test to confirm whether the improved predictive ability of the model 266 
including genetic variants significantly associated with IA was consistent after 50,000 iterations. 267 
Further details are included in supplementary material. All analyses were performed using R 268 
(http://www.r-project.org/). 269 
 270 
RESULTS 271 
A total of 781 patients were enrolled in this case-control study and, among them, one hundred 272 
and forty-nine were diagnosed with proven or probable IA according to the revised EORTC/MSG 273 
definitions. The remaining 632 patients showed no evidence for proven or probable IA. Baseline 274 
and clinical characteristics of IA and non-IA patient groups are summarized in Table 2. Overall, IA 275 
and non-IA patients had a similar mean age (52.67 vs. 52.79, P=0.935) but IA patients showed a 276 
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significantly higher male to female gender ratio when compared with those patients with no 277 
evidence of IA (1.81 vs. 1.19, P=0.031). In addition, the percentage of patients diagnosed with 278 
ALL was significantly higher in IA compared with non-IA patients (16.11% vs. 8.23%, P=0.006) 279 
whereas the percentage of patients with AML was significantly lower in IA compared to non-IA 280 
cases (67.11% vs. 76.74%, P=0.020). Interestingly, we also observed a significantly lower 281 
proportion of IA cases among those receiving posaconazole prophylaxis (P=0.017). 282 
 283 
Thirty-six genetic variants within 14 immune-modulating genes were initially genotyped in 593 284 
high-risk patients (113 IA and 480 non-IA patients). Logistic regression analysis revealed that 285 
patients carrying the IL4Rrs2107356A/A and the VEGFArs2146323A and VEGFArs6900017T alleles had a 286 
significantly increased risk of IA (OR=2.05, 95%CI 1.24-3.40; OR=1.63, 95%CI 1.02-2.61 and 287 
OR=1.76, 95%CI 1.02-3.03, respectively) whereas patients carrying the IL12Brs3212227C and 288 
IFNγrs2069705C alleles showed a significantly decreased risk of developing the disease (OR=0.57, 289 
95%CI 0.35-0.93 and OR=0.56, 95%CI 0.36-0.88, respectively; Table 3). When a log-additive 290 
model was assumed, we also found a significant association between the VEGFArs2146323 and 291 
VEGFArs6900017 SNPs and an increased risk of IA (per-allele OR=1.45, 95%CI 1.04-2.03 and per-292 
allele OR=1.73, 95%CI 1.08-2.77) and a statistically significant association of the IFNγrs2069705 293 
SNP with a decreased risk of developing IA (per-allele OR=0.69, 95%CI 0.49-0.97).  294 
 295 
In order to further confirm these significant associations, the study cohort was extended by 296 
recruiting 188 additional patients, 36 of whom were diagnosed with proven or probable IA. Given 297 
the low number of proven and probable IA cases, we could not consider this second population 298 
as an independent population for replication. An overall association analysis including 781 299 
patients (149 IA and 632 non-IA patients) confirmed that carriers of the IL4Rrs2107356A/A and 300 
IL8rs2227307G/G genotypes had a significantly increased risk of IA when compared with those 301 
carrying the wild type allele (OR=1.92, 95%CI 1.20-3.09 and OR=1.73, 95%CI 1.06-2.81) 302 
whereas those subjects harbouring the IL12Brs3212227C and IFNγrs2069705C alleles showed a 303 
decreased risk of developing the infection (OR=0.60, 95%CI 0.38-0.96 and OR=0.63, 95%CI 304 
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0.41-0.97, respectively). When we tested the allele-dose effect of significant SNPs, we found 305 
that the IL12Brs3212227 polymorphism was significantly associated with a reduced risk of getting 306 
the infection (per-allele OR=0.67, 95%CI 0.45-0.99; Table 3). As part of these association 307 
analyses, we also performed haplotype analysis that confirmed that none of these 308 
polymorphisms were part of risk haplotypes. We only observed a significant association with IA 309 
for a relatively rare IFNγTC haplotype whose effect was likely due to the IFNγrs2069705 SNP 310 
(OR=0.34, 95%CI 0.13-0.88; Supplementary Table 1). 311 
 312 
Interestingly, a logistic regression analysis restricted to allo-HSCT patients and considering only 313 
donor genotypes and episodes of IA that occurred after transplantation (n=171) also showed that 314 
the effect of the IL4R2107356 and IFNγrs2069705 SNPs on the risk of IA was considerably stronger in 315 
allo-HSCT patients compared to those patients who did not undergo transplantation (OR=5.63, 316 
95%CI 1.98-16.05 vs. OR=1.48, 95%CI 0.81-2.71 and OR=0.24, 95%CI 0.10-0.59 vs. OR=0.86, 317 
95%CI 0.52-1.45; respectively; Table 4). In this allo-HSCT-stratified analysis, we also found that 318 
allo-HSCT patients carrying the VEGFArs3024994T allele showed an increased risk of IA when 319 
compared with those allo-HSCT patients carrying the wild type genotype/allele (OR=4.48, 95%CI 320 
1.25-16.08; Table 4).  321 
 322 
Although none of the reported overall, haplotype and allo-HSCT-stratified associations remained 323 
significant after correction for multiple testing (PMeff_correction=0.0004), the association of 324 
IL4Rrs2107356 and IFNγrs2069705 polymorphisms showed a marginal level of significance in allo-325 
HSCT patients when a recessive and dominant model were respectively assumed (PREC=0.0009 326 
and PDOM=0.0011, respectively). Considering these results and those showing a suggestive 327 
association between IL12Brs3212227 SNP and risk of IA, we decided to evaluate whether the 328 
IL4Rrs2107356, IL8rs2227307, IL12Brs3212227 and IFNγrs2069705 variants could have a functional effect in 329 
modulating the strength of immune responses against specific Aspergillus antigens and/or 330 
stimulatory molecules. For that purpose, we first investigated whether IFNγrs2069705 and 331 
IL4Rrs2107356 but also IL12Brs3212227 and IL8rs2227307 variants correlated with the ability of monocyte-332 
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derived macrophages to efficiently kill fungal conidia. Interestingly, we found that macrophages 333 
from donors carrying the IFNγrs2069705C allele showed a significantly increased capability to kill 334 
fungal spores that those from subjects carrying the wild type genotype (TT vs. TC, P=0.0043; TT 335 
vs CC, P=0.0012; and TT vs. TC+CC, P=0.0003; Figure 1A). No differences in killing ability were 336 
observed in macrophages from donors carrying the IL4Rrs2107356A/A and IL8rs2227307G/G genotypes 337 
or IL12Brs3212227C allele in comparison with their respective wild type allele/genotype (Figure 1B-338 
D).  339 
 340 
Motivated by these results, we also decided to investigate whether the presence of the above-341 
mentioned SNPs correlated with cytokine levels after stimulation of PBMCs from healthy donors 342 
with fungal antigens (zymosan) or stimulatory molecules (LPS and PHA). These in vitro 343 
stimulation experiments revealed that carriers of the IFNγrs2069705C allele showed an increased 344 
production of IFNγ after 4 days of incubation with LPS or PHA and when both stimulating 345 
reagents were used in combination (PLPS=0.057, PPHA=0.036 and PLPS+PHA=0.030; Figure 2A and 346 
Supplementary Table 2). We also observed that donors carrying the IFNγrs2069705C allele showed 347 
a drastic increase in the production of TNF at almost all time points when compared with those 348 
bearing the wild type genotype (PPHA-72h=0.045, PLPS+PHA-72h=0.018, PLPS-96h=0.058, and PLPS+PHA-349 
96h=0.0058; Figure 2B and Supplementary Table 2). In addition, we observed that subjects 350 
carrying the IFNγrs2069705C allele tended to have an increased production of IL12p70 when 351 
compared with those carrying the wild type genotype (Figure 2C and Supplementary Table 2). 352 
No correlation between IL12p70 and IL8 levels and IL12Brs3212227 and IL8rs2227307 genotypes was 353 
found. These findings suggest that the IFNγrs2069705 SNP might contribute to modulate the risk of 354 
IA likely through the regulation of IFNγ mRNA levels.  355 
 356 
In order to test this hypothesis, we measured IFNγ mRNA expression in PBMCs from healthy 357 
donors (n=21) that were grouped according to the IFNγrs2069705 genotype. Importantly, we found 358 
that carriers of the IFNγrs2069705C allele (C/T+CC) showed a significantly increased level of IFNγ 359 
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mRNA when compared with those carrying the wild type genotype (40.85±11.65 vs. 13.87±5.43, 360 
P=0.049; Figure 3A and 3B). Although this result pointed toward a role of this SNP in modulating 361 
IFNγ gene expression in PBMCs, we decided to further confirm this result by looking at the 362 
publicly available blood expression quantitative trait loci (eQTL) browser   363 
(http://genenetwork.nl/bloodeqtlbrowser/). Of note, we found that, in agreement with our gene 364 
expression data, this variant located in the promoter region of the gene (but also those 365 
neighboring SNPs within the same linkage disequilibrium block) showed a positive correlation 366 
with IFNγ mRNA expression level that ranged between P=1.01•10-3 and P=1.70•10-3 367 
(Supplementary Figure 1).  368 
 369 
Next, we analysed the correlation between the IL4Rrs2107356 SNP and IL4R mRNA expression 370 
levels in whole blood samples collected from healthy donors (n=43) and in monocyte-derived 371 
macrophages at baseline and after in vitro stimulation with A. fumigatus conidia (n=12). Gene 372 
expression data in blood samples did not show differences in IL4R mRNA expression levels 373 
between homozygotes (GG vs. AA, P=0.304) but they showed a significantly increased level of 374 
expression in heterozygotes when were compared either with wild type or mutant homozygotes 375 
(AG vs. GG, P=0.0045 and AG vs. AA, P=0.031, respectively; Figure 3C). When carriers of the 376 
IL4Rrs2107356AA genotype were compared with those carrying the wild type allele (according to the 377 
genetic model used in our genetic analysis), we failed to find statistical differences in IL4R 378 
mRNA expression levels (PAAvs.GG+AG=0.2937; Figure 3D). These findings did not support our 379 
hypothesis suggesting a functional effect for this promoter polymorphism on mRNA expression 380 
but were in agreement with those data from the blood eQTL browser that reported no 381 
association of this promoter variant with IL4R mRNA expression levels in PBMCs. In line with 382 
these results, we neither found any correlation between the IL4Rrs2107356 variant and IL4R mRNA 383 
expression levels in monocytes-derived macrophages at baseline and after stimulation with A. 384 
fumigatus conidia (Figure 3E and 3F). The lack of correlation between this promoter 385 
polymorphism and IL4R protein level was also confirmed by flow cytometry analysis in different 386 
immune cell types (CD19+, CD14+ and CD3+, cells; Figure 3G). We only found a significantly 387 
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increased level of IL4R in CD19+ cells in heterozygotes when compared with those subjects 388 
carrying the AA genotype (P=0.032; Figure 3G), which was in line with our gene expression data 389 
in blood samples from healthy donors and confirmed that the effect attributed to this promoter 390 
variant cannot be explained by changes in mRNA or protein expression levels. Given that IL4R 391 
is internalized in a time-dependent manner after stimulation with IL4, we could not confidently 392 
measure the correlation of the IL4R2107356 SNP and IL4R protein levels under stimulation 393 
conditions (data not shown).  394 
  395 
Finally, considering the association of some of the immune-modulating SNPs with the risk of 396 
developing IA and given the correlation of some of these genetic markers with cytokine levels, 397 
we tested the capacity of these variants to predict with confidence the disease risk. We 398 
assessed the predictive capacity of a model built with “significant SNPs” and demographic and 399 
clinical variables in comparison with a reference model including only demographic and clinical 400 
variables. Despite the modest population size, we found that a predictive model including 4 401 
variants associated with IA, age, gender, allo-HSCT and antifungal prophylaxis status showed 402 
an improvement in discriminatory ability to predict the disease when compared with the 403 
reference model (AUC=0.659, 95%IC 0.596-0.722, P=0.000005 vs. AUC=0.564, 95%IC 0.499-404 
0.630, P=0.064; P-2_log_likehood_ratio_test=0.00052; Table 5 and Figure 4). Importantly, we also 405 
observed that a model built with a similar number of “non-significant SNPs”, together with 406 
demographic and clinical variables, did not show any significant change in predictive capacity 407 
when compared with the reference model (Supplementary Table 3), which confirmed the utility of 408 
significant SNPs in predicting IA. The consistency of the predictive results was supported 409 
through a 50.000 permutation test that showed that none of the 50.000 permuted models 410 
showed a better prediction capacity than our genetic model built with SNPs significantly 411 
associated with IA (AUCsort-average=0.6001, SDsort-AUC=0.0158, Z score=3.7361 and PZ_score-412 
value_(50.000perm)=9.34•10-05; Table 5 and Supplementary material). 413 
 414 
DISCUSSION 415 
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In this study, we report an association between genetic variants within IL4R, IL8, IL12B and IFNγ 416 
genes and the risk of developing IA. Carriers of the IL4Rrs2107356A/A and IL8rs2227307G/G genotypes 417 
had a significantly increased risk of developing the infection whereas patients carrying the 418 
IL12Brs3212227C and IFNγrs2069705C alleles showed a substantially decreased risk of IA when 419 
compared with those harbouring the wild type allele/genotype. Although none of these 420 
associations persisted after a restrictive correction for multiple testing, we found that the 421 
association of the IL4Rrs2107356 and IFNγrs2069705 polymorphisms reached marginal significance in 422 
the allo-HSCT patient population, which pointed towards an impact of these variants in 423 
modulating the risk of developing IA, particularly in high-risk populations. Based on these results 424 
but also those suggesting overall associations of polymorphisms within the IL4R, IL8, IL12B and 425 
IFNγ genes at the conventional significance threshold of P≤0.05, it seems plausible to suggest 426 
that polymorphisms within these genes may affect gene function and therefore contribute to the 427 
pathogenesis of IA. We hypothesized that both IL4Rrs2107356 and IFNγrs2069705 polymorphisms, 428 
located in the promoter region of their respective genes, may affect gene expression and, 429 
consequently, have an effect in modulating IL4- and IFNγ-mediated immune responses against 430 
Aspergillus. Likewise, we hypothesized that IL8rs2227307 and IL12Brs3212227 intronic polymorphisms 431 
might affect alternative splicing of IL8 and IL12B mRNA and even alter mRNA expression 432 
thereby dysregulating IL8- and IL12-mediated Th1 immune responses against fungal pathogens. 433 
In line with these arguments, a number of previous studies have reported associations of these 434 
polymorphisms with immune-related diseases (55, 56) and infections (57-60) including IA (45). 435 
In particular, we confirmed an association previously reported by Mezger et al. (2008) between 436 
the IFNγrs2069705 SNP and the risk of IA (45). This supports our hypothesis that this association is 437 
likely to be true and that this variant may play a role in modulating the immune response against 438 
Aspergillus.  439 
 440 
Recent studies in humans and animal models have demonstrated that IL4/IL4R, IL8, IL12 and 441 
IFNγ have a central role in IA (19, 61-65). In particular, IFNγ seems to be a key factor as its 442 
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enhanced production (14, 66) or its therapeutic administration (63), boosts the production of free 443 
oxygen radicals and the neutrophil-mediated damage of fungal hyphae and promotes resistance 444 
to the infection (19, 67). It is also well documented that the production of IL8 and IL12p70 by 445 
epithelial and dendritic cells in response to conidia enhances Th1-mediated immune responses 446 
(61, 68, 69) and increases resistance to IA (62) whereas its neutralization produces a marked 447 
increase in susceptibility to IA (15, 19). IL12p70 also mediates enhanced cytotoxic activity of NK 448 
cells and CD8+-T cells and promotes the secretion of IFNγ by CD4+-T cells, which is an essential 449 
process for an efficient clearance of inhaled Aspergillus fumigatus spores. Conversely, IL4 450 
secretion activates Th2-CD4+-T cell immune responses and leads to a significant decrease in Th1 451 
immune responses and, consequently, increases susceptibility to Aspergillus infection (19, 70). 452 
Similarly, it has also been demonstrated that the lack of IL4 cytokine increases Th1 immune 453 
responses characterized by high production of IL12 and an enhanced IL12-mediated production 454 
of IFNγ by T lymphocytes thereby leading to an increase in resistance to developing the infection 455 
(19). 456 
 457 
In light of these results and in order to better characterize the role of IFNγ, IL4R, IL8 and IL12B 458 
polymorphisms in modulating immune responses against fungal antigens and/or specific 459 
stimulatory molecules, we proceeded to perform functional assays in PBMCs and monocyte-460 
derived macrophages from healthy donors. Importantly, we found that subjects carrying the 461 
IFNγrs2069705C allele showed an increased ability to kill A. fumigatus conidia than those carrying 462 
the wild type allele. This important finding support our genetic findings but also those from a 463 
previous study (45) suggesting that IFNγrs2069705 promoter variant might play a key role in 464 
modulating the strength of immune responses against Aspergillus likely through the modulation 465 
on IFNγ mRNA expression. Importantly, we also observed that, under stimulating conditions, 466 
PBMCs from carriers of the IFNγrs2069705C allele showed an increased production of IFNγ and TNF 467 
cytokines than those individuals carrying the wild type allele. In addition to this, we found that the 468 
IFNγrs2069705 SNP correlated with IFNγ mRNA levels in PBMCs from healthy donors, which again 469 
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suggested that this polymorphism or another causative polymorphism in strong linkage 470 
disequilibrium with it may be involved not only in the control of IFNγ production but also in the 471 
subsequent induction of TNF production. Taking all these findings together, we propose a central 472 
role for this variant in determining the risk of IA in allo-HSCT and in leukaemia patients 473 
undergoing intensive chemotherapy. 474 
 475 
Although genetic data suggested that polymorphisms within IL4R, IL8 and IL12B influence the 476 
risk of developing IA, functional experiments did not show any correlation between these SNPs 477 
and their respective mRNA and/or protein levels. Therefore, we suggest that these variants 478 
might exert their biological function by modulating other biological processes such as mRNA 479 
processing (splicing or turnover) or mRNA stability or even act at post-transcriptional level. 480 
Further studies are now warranted to replicate our findings and to experimentally identify the 481 
functional role of these SNPs in determining the risk of IA.   482 
 483 
Finally, given the genetic and/or functional effect observed for variants within IFNγ, IL4R, IL8, 484 
IL12B and VEGFA genes, we found also interesting to determine the impact of these variants in 485 
predicting the disease risk. We found that a model built with IL8rs2227307, IL12Brs3212227, IFNγrs2069705 486 
and VEGFArs6900017 SNPs showed a significantly improved discriminatory ability to predict the 487 
disease when it was compared with a model that included demographic and clinical variables. 488 
Importantly, when a similar number of “non-significant SNPs” were added to the reference 489 
model, we did not observe any significant change in predictive capacity, which confirmed that 490 
only a model built with these significant SNPs could have capacity to predict the infection. In 491 
support of this finding, we also observed that the AUC of this model was systematically higher 492 
than the AUC observed for 50.000 iterative models, which emphasizes the importance of 493 
considering predictive models to assist in the clinical decision-making process and to improve in 494 
novel strategies to prevent IA occurrence.  495 
  496 
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This study has both strengths and limitations. Study strengths include a multicentre population-497 
based design, a relatively large sample size, and the high number of genetic polymorphisms 498 
analysed. This allowed us for the first time to perform predictive analyses to assess the potential 499 
utility of genetic variants in predicting with confidence the risk of developing IA. Potential 500 
weaknesses include limited antifungal prophylaxis data availability for a subset of patients and a 501 
relatively low number of proven or probable IA cases that limited the study’s statistical power to 502 
rule out spurious associations. To minimize this limitation, the most relevant associations were 503 
functionally validated.  504 
 505 
In conclusion, our data suggest that immune-modulating polymorphisms have an impact on the 506 
risk of IA and that genotyping of these variants could help to predict the risk of IA and therefore 507 
be useful to establish a risk-adapted anti-fungal prophylaxis strategy. 508 
 509 
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TABLE AND FIGURE LEGENDS 777 
Table 1. Selected SNPs within immune-modulating genes. 778 
 779 
Abbreviations: SNP, single nucleotide polymorphisms, UTR, untranslated region. References included in this 780 
table are listed in the supplementary material. 781 
 782 
Table 2. Baseline and clinical characteristic of IA and non-IA patient groups. 783 
 784 
Abbreviations: HSCT: Hematopoietic stem cell transplantation, AML: acute myeloid leukemia, ALL: acute 785 
lymphoid leukemia; UHS, University hospital of Salamanca (Spain); GHV, General hospital of Valencia (Spain); 786 
PCRAGA clinical trial (EU clinical trial number: 2010-019406-17); CSC, Università Cattolica del S. Cuore, Rome 787 
(Italy); MO, University of Modena and Reggio Emilia, Modena (Italy). P≤0.05 was considered significant. 788 
* Some patients had several prophylactic drugs.  789 
† Prophylaxis status was only available in 99 subjects (15 IA and 72 non-IA patients). 790 
∂ Percentage calculated according to the number of patients with prophylaxis data available. 791 
 792 
Table 3. Association of polymorphisms within immunoregulatory genes and invasive 793 
aspergillosis. 794 
 795 
Abbreviations: OR, odds ratio; CI, confidence interval. Abbreviations: n/s, not specified; SNP, single nucleotide 796 
polymorphism; UTR, untranslated region. Estimates were adjusted for age, sex, country of origin, allo-SCT, and 797 
prophylaxis status (ever use of prophylaxis). P<0.05 in bold.  798 
 799 aDiscovery population: aspBIOmics+PCRAGA+Valencia+Salamanca populations; N=593 hematological patients 800 
bOverall: n=781; after extension with 188 high-risk patients [39 HSCT and 149 non-HSCT patients]; 87 of them 801 
with prophylaxis data. 802 
†Estimates according a recessive model of inheritance.  803 
§SNP signifcantly associated with IA according a log-additive model of inheritance.  804 
 805 §IFNGrs2069705 (per-allele OR= 0.69, 95%CI 0.49-0.97; Ptrend=0.032). 806 §VEGFArs2146323 (per-allele OR= 1.45, 95%CI 1.04-2.03; Ptrend =0.029).  807 §VEGFArs6900017 (per-allele OR= 1.73, 95%CI 1.08-2.77; Ptrend=0.027).  808 §IL12Brs3212227 (per-allele OR= 0.67, 95%CI 0.45-0.99; Ptrend =0.040).  809 
 810 
 811 
Table 4. Association of immunoregulatory SNPs and IA in allo-HSCT patients (n=171). 812 
 813 
Abbreviations: OR, odds ratio; CI, confidence interval. Abbreviations: n/s, not specified; SNP, single nucleotide 814 
polymorphism; UTR, untranslated region. Estimates were adjusted for age, sex, country of origin, severe 815 
neutropenia, and prophylactic status (ever having prophylaxis). P<0.05 in bold.  816 
 817 
aOverall population (Discovery population+extension). 818 
†Estimates according a recessive model of inheritance.  819 
§SNP associated with IA infection according to a log-additive model of inheritance.  820 
*Estimates calculated according a co-dominant model (homozygotes for the rare allele were not found). 821 
 822 
§IL4Rrs2107356 (per-allele OR= 2.17, 95%CI 1.18-3.98; Ptrend=0.0097).  823 §IFNGrs2069705 (per-allele OR= 0.50, 95%CI 0.26-0.95; Ptrend=0.027).  824 §VEGFArs3024994 (per-allele OR= 3.19, 95%CI 1.08-9.45; Ptrend=0.033).  825 
 826 
Table 5. Discriminative value AUC for models including immune-modulating variants.  827 
 828 
aIncluding age, gender, allo-HSCT and prophylactic status as variables never dropped from models. 829 
**IL4Rrs2107356 and VEGFArs2146323 polymorphisms were not significant and were dropped from the model. 830 
Residual deviance (Reference model): 433.21  831 
Residual deviance (Significant SNPs model): 413.31 832 
After removing missing values, 455 subjects (85 IA and 370 non-IA cases) were available for prediction capacity 833 
analysis. 834 
 835 
 836 
 837 
 838 
 839 
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 840 
Figure 1. Fungicidal activity of monocyte-derived macrophage according to IFNγ [A], IL12B [B], 841 
IL4R [C] and IL8 [D] genotypes. 842 
 843 
 844 
Figure 2. IFNγ, TNFα and IL12p70 cytokine levels on stimulated PBMCs according to the 845 
IFNγrs2069705 genotypes. 846 
 847 
PBMCs from healthy donors were stimulated with Zymosan (5μg/ml) and PHA (2 μg/ml) alone or in combination 848 
with LPS (100 ng/ml). Supernatants were harvested for IFNγ, TNFα and IL12p70 analysis at 72 and 96h. 849 
 850 
 851 
Figure 3. IFNγ [A and B] and IL4R mRNA [C-F] and protein [G] expression levels according to 852 
the IL4Rrs2107356 genotypes. 853 
 854 
Correlation between IFNγrs2069705 genotypes and IFNγ mRNA expression levels were analysed in PBMCs from 855 
healthy donors at baseline or stimulated with Aspergillus conidia [A and B]. Correlation between IL4Rrs2107356 856 
genotypes and IL4R mRNA expression levels were analysed in blood samples from healthy donors [C and D] and 857 
in monocyte-derived macrophages at baseline or stimulated with Aspergillus conidia [E and F]. Correlation 858 
between this promoter variant and IL4R protein levels were also analysed in different immune cells (CD19+, CD14+ 859 
and CD3+) by flow cytometry [G].  860 
 861 
  862 
Figure 4. Receiver operating characteristics (ROC) curve analysis. 863 
 864 
ROC curves summarize the accuracy of prediction for each particular model. The model including SNPs 865 
significantly associated with IA and demographic and clinical variables (marked in blue) showed a significantly 866 
improved predictive capacity comparared with a reference model including only demographic and clinical variables 867 
(marked in red). 868 
AUC=0.659 vs. AUC=0.564. 869 
 870 
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Table 1. Selected SNPs within immune-modulating genes. 
Gene name Gene symbol_SNP dbSNP rs# Nucleotide 
substitution 
Aa 
change/Location 
Reported associations with infectious 
diseases / reported or potential functionality 
References 
       
Interleukin 4 (IL4) IL4_-1098 rs2243248 G/T Promoter Associated with chronic disseminated candidiasis (1) 
 IL4_Ex1-168 rs2070874 C/T Intronic Unknown  
 IL4_IVS2-1443 rs2243268 A/C Intronic Unknown  
 IL4_ IVS3-9 rs2243290 A/C Intronic Unknown  
       
Interleukin 4 receptor (IL4R) IL4R_-29429 (-3223) rs2057768 A/G Promoter Associated with soluble IL4R protein levels (2) 
 IL4R_-28120 (-1914) rs2107356 A/G Promoter Unknown  
 IL4R_Ex11+828 rs1801275 A/G Q576R Associated with enhanced responsiveness to IL4 (3, 4) 
       
Interleukin 8 (IL8) IL8_-251 rs4073 A/T Promoter Associated with increased levels of IL-8 and 
susceptibility to bacterial urinary tract infection, 
recurrent Clostridium difficile infection, AIDS, 
Helicobacter pylori related gastric diseases and 
mycetoma 
(5-8) 
 IL8_ IVS1+230 (+396) rs2227307 G/T Intronic Associated with susceptibility to periodontitis (9) 
       
CXC-Chemokine receptor 1 (IL8RA) CXCR1_Ex2+860 rs2234671 G/C S276T Associated with chronic HBV infection. Predicted 
to affect IL8 signalling (Benign; Polyphen) 
(10) 
       
CXC-Chemokine receptor 2 (IL8RB) CXCR2_Ex3-1010 rs1126580 A/G Intronic Unknown  
Interleukin 10 (IL10) IL10_IVS1-286 rs3024491 G/T Intronic Unknown  
 IL10_Ex5+210 rs3024496 C/T Intronic IL10_Ex5+210G alleles is associated with the 
decreased production of IL-10 by peripheral blood 
leukocytes in response to helminth infection 
(11) 
       
Interleukin 12 alpha (IL12A) IL12A_IVS2-798 rs582054 A/T Intronic Unknown  
       
Interleukin 12 beta (IL12B) IL12B_Ex8+159 (+1188) rs3212227 A/C Intronic IL12B_+1188C allele is associated with an 
increased risk of lepromatous leprosy 
(12) 
       
Interleukin 13 (IL13) IL13_-1069 rs1800925 C/T Promoter Alters the expression of IL13 and the binding of 
nuclear factors to the IL13 promoter.  Associated 
with an increased risk of severe respiratory 
syncytial virus (RSV) infection. 
(13, 14) 
 IL13_Ex4+98 rs20541 C/T R144Q Modifies the IL13-mediated Th2 effector functions 
and correlates with IL13 activity and levels (114Q 
carriers have higher levels of IL13 compared to 
144R) 
(15) 
 IL13_IVS3-24 rs1295686 A/G Intronic Unknown  
       
Interferon gamma (IFNγ) IFNG_-1615 rs2069705 C/T Promoter Associated with a reduced risk of IA (16) 
 IFNG_IVS3+284 (+2109) rs1861494 C/T Intronic Unknown  
       
Interferon gamma receptor 2 (IFNγR2) IFNGR2_Ex7-128 rs1059293 C/T Intronic Unknown  
 IFNGR2_Ex2-16 rs9808753 A/G Q64R Predicted to affect IFNγ signalling (Possibly 
damaging; Polyphen) 
 
       
C-C chemokine receptor type 5 (CCR5) CCR5_IVS1+246 rs1799987 A/G Intronic Associated with CCR5 protein levels and HIV-1 (17, 18) 
 CCR5_IVS1+151 rs2734648 G/T Intronic Part of an haplotype associated with HIV-1 (19) 
 
Abbreviations: SNP, single nucleotide polymorphisms, UTR, untranslated region. References included in this table are listed in the supplementary material. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Macrophage migration inhibitory factor 
(MIF) 
MIF_-173 rs755622 C/G Promoter MIF_-173CC is associated with pulmonary 
tuberculosis 
(20, 21) 
       
Vascular Endothelial Growth Factor 
alpha (VEGFA) 
VEGFA_-2578 rs699947 A/C Promoter VEGF_-2578CC was associated with higher or 
lower VEGF expression. Associated with urinary 
tract infection.  
(22-24) 
 
VEGFA_-7 rs25648 C/T Promoter Associated with higher levels of VEGFA mRNA (25) 
 VEGFA_IVS2+1378 rs3024994 C/T Intronic Unknown  
 VEGFA_IVS7-919 rs3025035 C/T Intronic Unknown  
 VEGFA_6112 rs2146323 A/C - Unknown  
 VEGFA_IVS-99 rs3024997 A/G Intronic Unknown  
 VEGFA_IVS7+763 rs3025030 C/G Intronic  Unknown  
 VEGFA_5530 rs998584 G/T - Unknown  
 VEGFA_5958bp 3’of STP rs6899540 A/C - Unknown  
 VEGFA_6119bp 3’of STP rs6900017 C/T - Unknown  
 VEGFA_Near gene rs6905288 A/G -   
       
Table 2. Baseline and clinical characteristic of patients with or without invasive aspergillosis (IA). 
Phases 1 aspBIOmics consortium + UHS-GHV-PCR-AGA populations
 overall (n=593) IA patients (n=113) non-IA patients (n=480) P value 
Demographic variables     
age (range) 51.46 ± 15.08 51.70 ± 13.20 51.40 ± 15.51 0.834 
sex ratio (male/female) 1.27 (332/261) 1.90 (74/39) 1.16 (258/222) 0.031 
Haematological disease     
AML      412 (69.48)    66 (58.41)  346 (72.08) 0.006
ALL        73 (12.31)    23 (20.35)     50 (10.42) 0.006 
other      108 (18.21)    24 (21.24)     84 (17.50) 0.429 
allo-HSCT      299 (50.42)    65 (57.52)   234 (48.75) 0.116 
Ever received prophylaxis *     
posaconazole       73 (12.31) 10 (8.85)     63 (13.13) 0.277 
itraconazole     49 (8.26)   13 (11.50)   36 (7.50) 0.230 
echinocandins     30 (5.06)   2 (1.77)    28 (5.83) 0.125
voriconazole     21 (3.54)   6 (5.31)    15 (3.13) 0.397 
amphotericin B       4 (0.67)   0 (0.00)      4 (0.83) 0.738 
Never received prophylaxis     450 (75.89)   87 (76.99)     363 (75.63) 0.855 
Phase 2 CSC-MO + VNH population 
 overall (n=188) IA patients (n=36) non-IA patients (n=152) P value 
Demographic variables     
age (range) 56.93 ± 18.12 55.75 ± 19.50 57.21 ± 17.84 0.665 
sex ratio (male/female) 1.32 (107/81) 1.57 (22/14) 1.27 (85/67) 0.705 
Haematological disease     
AML 173 (92.02) 34 (94.44) 139 (91.45) 0.799 
ALL   3 (1.60) 1 (2.78)   2 (1.32) 0.912 
other 12 (6.38) 1 (2.78)  11 (7.24) 0.545 
allo-HSCT   39 (20.74) 3 (8.33)   36 (23.68) 0.069 
Ever received prophylaxis†     
posaconazole 40 (40.40)   3 (11.11) 37 (51.39) 0.0007
itraconazole        7 (7.07)   3 (11.11) 4 (5.56) 0.603 
echinocandins 1 (1.01) 0 (0.00) 1 (1.39) 0.608 
voriconazole 2 (2.02) 0 (0.00) 2 (2.78) 0.942 
amphotericin B      16 (16.16) 2 (7.41)            14 (19.44) 0.253 
Never received prophylaxis∂ 69 (69.70) 24 (88.89)  45 (62.50) 0.022
Phases 1+2 aspBIOmics consortium + UHS-GHV-PCR-AGA + CSC-MO population
 overall (n=781) IA patients (n=149) non-IA patients (n=632) P value 
Demographic variables     
age (range) 52.77 ± 16.03 52.67 ± 15.00 52.79 ± 16.27 0.935 
sex ratio (male/female) 1.28 (439/342) 1.81 (96/53) 1.19 (343/289) 0.031 
Haematological disease     
AML     585 (74.90)  100 (67.11)   485 (76.74) 0.020 
ALL   76 (09.73)    24 (16.11)     52 (08.23) 0.006 
other     120 (15.36)    25 (16.78)     95 (15.03) 0.685
allo-HSCT 338 (43.28)    68 (45.64)   270 (42.72) 0.579 
Ever received prophylaxis     
posaconazole 113 (16.33) 13 (9.29)   100 (18.12) 0.017
itraconazole 56 (8.09)   16 (11.43)   40 (7.25) 0.148 
echinocandins 31 (4.48)   2 (1.43)   29 (5.25) 0.085 
voriconazole 23 (3.32)   6 (4.29)   17 (3.08) 0.655 
amphotericin B 20 (2.89)   2 (1.43)   18 (3.26) 0.383 
Never received prophylaxis∂ 519 (75.00) 111 (79.29)   408 (73.91) 0.229 
Abbreviations: HSCT: Haematopoietic stem cell transplantation, AML: acute myeloid leukemia, ALL: acute 
lymphoid leukemia; UHS, University hospital of Salamanca (Spain); GHV, General hospital of Valencia (Spain); 
PCRAGA clinical trial (EU clinical trial number: 2010-019406-17); CSC, Università Cattolica del S. Cuore, Rome 
(Italy); MO, University of Modena and Reggio Emilia, Modena (Italy) and Virgen de las Nieves University 
hospital (VNH). P≤0.05 was considered significant. 
* Some patients had several prophylactic drugs.  
† Prophylaxis status was only available in 99 subjects (15 IA and 72 non-IA patients). 
∂ Percentage calculated according to the number of patients with prophylaxis data available. 
Table 3. Associations found between immunoregulatory polymorphisms and invasive aspergillosis. 
 
Variant_dbSNP Gene OR (95% CI)a Pvalue OR (95% CI)b Pvalue 
      rs2243248 IL4 1.19 (0.63-2.26) 0.59   
rs2070874 IL4 0.91 (0.53-1.55) 0.72   
rs2243268 IL4 0.85 (0.52-1.38) 0.50   
rs2243290 IL4 0.67 (0.39-1.16) 0.14   
rs2057768 IL4R 1.20 (0.75-1.92) 0.44   
rs2107356 IL4R  2.05 (1.24-3.40)† 0.0063  1.92 (1.20-3.09)† 0.008 
rs1801275 IL4R 1.00 (0.63-1.59) 0.99   
rs4073 IL8 1.02 (0.64-1.61) 0.95   
rs2227307 IL8  1.72 (1.00-2.94)† 0.049   1.73 (1.06-2.81)† 0.031 
rs2234671 IL8RA 1.57 (0.80-3.08) 0.20   
rs1126580 IL8RB 1.50 (0.88-2.54) 0.13   
rs3024491 IL10 1.09 (0.67-1.78) 0.72   
rs3024496 IL10 1.16 (0.71-1.90) 0.55   
rs582054 IL12A 1.09 (0.64-1.84) 0.76   
rs3212227 IL12B 0.57 (0.35-0.93) 0.021  0.60 (0.38-0.96)§ 0.029 
rs20541 IL13 0.76 (0.46-1.24) 0.26   
rs1800925 IL13 0.85 (0.54-1.36) 0.51   
rs1295686 IL13 0.73 (0.45-1.16) 0.18   
rs2069705 IFNG  0.56 (0.36-0.88)§ 0.012  0.63 (0.41-0.97) 0.035 
rs1861494 IFNG 0.74 (0.47-1.17) 0.20   
rs1059293 IFNGR2 0.98 (0.57-1.67) 0.93   
rs9808753 IFNGR2 1.10 (0.65-1.85) 0.72   
rs1799987 CCR5 1.40 (0.83-2.36) 0.20   
rs2734648 CCR5 1.07 (0.67-1.71) 0.76   
rs755622 MIF 1.38 (0.84-2.25) 0.20   
rs25648 VEGFA 1.11 (0.63-1.97) 0.72   
rs699947 VEGFA 1.28 (0.75-2.18) 0.35   
rs3024994 VEGFA 1.61 (0.86-3.03) 0.15   
rs3025035 VEGFA 1.31 (0.78-2.22) 0.31   
rs2146323 VEGFA 1.63 (1.02-2.61) 0.040  1.46 (0.95-2.27) 0.085 
rs3024997 VEGFA 1.04 (0.67-1.61) 0.87   
rs3025030 VEGFA 1.00 (0.58-1.70) 0.99   
rs998584 VEGFA 0.66 (0.41-1.06) 0.088   
rs6899540 VEGFA 0.84 (0.51-1.40) 0.50   
rs6900017 VEGFA  1.76 (1.02-3.03)§ 0.046  1.47 (0.87-2.47) 0.16 
rs6905288 VEGFA 0.83 (0.52-1.31) 0.42   
 
Abbreviations: OR, odds ratio; CI, confidence interval. Abbreviations: n/s, not specified; SNP, single nucleotide 
polymorphism; UTR, untranslated region. Estimates were adjusted for age, sex, country of origin, allo-SCT, and 
prophylaxis status (ever use of prophylaxis). P<0.05 in bold. P<0.0004 was defined as multiple testing significance 
threshold. 
 aPhase 1 (aspBIOmics + PCRAGA+Valencia+Salamanca populations; N=593 hematological patients). bOverall (N=781; after extension with 188 high-risk patients [39 HSCT and 149 non-HSCT patients]; 87 of them 
with prophylaxis data). †Estimates according a recessive model of inheritance.  §SNP signifcantly associated with IA according a log-additive model of inheritance.  
 
§IFNGrs2069705 (per-allele OR= 0.69, 95%CI 0.49-0.97; Ptrend=0.032). §VEGFArs2146323 (per-allele OR= 1.45, 95%CI 1.04-2.03; Ptrend =0.029).  §VEGFArs6900017 (per-allele OR= 1.73, 95%CI 1.08-2.77; Ptrend=0.027).  §IL12Brs3212227 (per-allele OR= 0.67, 95%CI 0.45-0.99; Ptrend =0.040).  
 
Table 4. Associations found between immunoregulatory SNPs and IA in allo-HSCT patients (n=171). 
 
Variant_dbSNP Gene OR (95%CI) Pvalue 
    rs2243248 IL4 0.93 (0.25-3.44) 0.91 
rs2070874 IL4 1.40 (0.56-3.52) 0.47 
rs2243268 IL4 1.15 (0.49-2.73) 0.75 
rs2243290 IL4 0.93 (0.35-2.45) 0.88 
rs2057768 IL4R 1.30 (0.56-3.03) 0.54 
rs2107356 IL4R    5.63 (1.98-16.05)†§ 0.0009 
rs1801275 IL4R 0.50 (0.20-1.24) 0.12 
rs4073 IL8 0.76 (0.33-1.73) 0.51 
rs2227307 IL8 1.21 (0.51-2.86) 0.67 
rs2234671 IL8RA 1.48 (0.42-5.15) 0.55 
rs1126580 IL8RB  2.39 (0.92-6.20)†  0.072 
rs3024491 IL10 1.08 (0.44-2.70) 0.86 
rs3024496 IL10 0.74 (0.30-1.83) 0.52 
rs582054 IL12A 1.73 (0.61-4.91) 0.29 
rs3212227 IL12B 0.64 (0.26-1.57) 0.32 
rs20541 IL13 0.80 (0.32-1.99) 0.63 
rs1800925 IL13 1.96 (0.84-4.58) 0.12 
rs1295686 IL13 0.53 (0.22-1.29) 0.16 
rs2069705 IFNG  0.24 (0.10-0.59)§ 0.0011 
rs1861494 IFNG 0.63 (0.27-1.49) 0.29 
rs1059293 IFNGR2 1.53 (0.59-3.97) 0.37 
rs9808753 IFNGR2 0.78 (0.29-2.09) 0.62 
rs1799987 CCR5 1.75 (0.65-4.69) 0.26 
rs2734648 CCR5 1.04 (0.44-2.48) 0.93 
rs755622 MIF  0.63 (0.25-1.61)* 0.33 
rs25648 VEGFA 1.39 (0.53-3.66) 0.51 
rs699947 VEGFA 0.51 (0.19-1.36) 0.18 
rs3024994 VEGFA  4.48 (1.25-16.08)§ 0.022 
rs3025035 VEGFA 1.96 (0.77-4.99) 0.16 
rs2146323 VEGFA 0.86 (0.38-1.97) 0.72 
rs3024997 VEGFA 0.71 (0.31-1.62) 0.41 
rs3025030 VEGFA  1.11 (0.41-3.01)* 0.84 
rs998584 VEGFA 0.84 (0.32-2.22) 0.72 
rs6899540 VEGFA 0.62 (0.23-1.69) 0.34 
rs6900017 VEGFA 2.68 (0.97-7.42) 0.061 
rs6905288 VEGFA 1.04 (0.43-2.53) 0.92 
 
Abbreviations: OR, odds ratio; CI, confidence interval. Abbreviations: n/s, not specified; SNP, single 
nucleotide polymorphism; UTR, untranslated region. Estimates were adjusted for age, sex, country 
of origin, severe neutropenia, and prophylactic status (ever having prophylaxis). P<0.05 in bold. 
P<0.0004 was defined as corrected significance threshold. 
 †Estimates according a recessive model of inheritance.  §SNP associated with IA infection according to a log-additive model of inheritance.  
*Estimates calculated according a co-dominant model (homozygotes for the rare allele were 
not found).  
§IL4Rrs2107356 (per-allele OR= 2.17, 95%CI 1.18-3.98; Ptrend=0.0097).  §IFNGrs2069705 (per-allele OR= 0.50, 95%CI 0.26-0.95; Ptrend=0.027).  §VEGFArs3024994 (per-allele OR= 3.19, 95%CI 1.08-9.45; Ptrend=0.033).  
 
 
 
Table 5. Discriminative value AUC for models with or without immune-modulating variants.  
 
Reference model  
SNPs  P-value OR 95%CI AUC 95%CIa P-value 
Age  0.898 1.001 (0.985-1.017)   
Gender  0.033 1.721 (1.045-2.835)   
Allo-SCT  0.785 0.934 (0.570-1.529)   
Prophylactic status  0.790 1.080 (0.612-1.906) 0.564 (0.499-0.630)∂ 0.064 
Predictive model built with 4 significant SNPs* 
SNPs  P-value OR 95%CI AUC 95%CIa P-value 
IL8rs2227307  0.024 1.952 (1.093-3.489)   
IL12Brs3212227  0.016 0.508 (0.292-0.884)   
IFNGrs2069705  0.031 0.583 (0.358-0.952)   
VEGFArs6900017  0.040 1.814 (1.026-3.207)   
Age  0.951 1.001 (0.984-1.018)   
Gender  0.064 1.626 (0.972-2.719)   
Allo-SCT  0.757 0.923 (0.557-1.532)   
Prophylactic status  0.525 1.210 (0.672-2.179) 0.659 (0.596-0.722)∂ 0.000005 
aIncluding age, gender, allo-SCT and prophylactic status as variables never dropped from models. 
*IL4Rrs2107356 and VEGFArs2146323 polymorphisms were not significant and were dropped from the model. 
∂ These models showed a statistically different prediction capacity (-2log likehood ratio test, df=4, P=0.00052). 
Residual deviance (Reference model): 433.21  
Residual deviance (Significant SNPs model): 413.31 
After removing missing values, 455 subjects (85 IA and 370 non-IA cases) were available for prediction capacity analysis.  
Permutation analysis: Average AUC of null distribution (50.000 models)=0.6001; SD50.000AUC=0.0158; 
Z-score_value50.000perm=3.7361 and P50.000perm=9.34•10-05. 
